🔴 Nasus Pharma is trading 5.65% down today after first-half results showed wider net loss and going-concern risk

Nasus Pharma is trading at $3.42, down 5.65%, after releasing first-half 2026 financial results on August 17, 2026:

• Net loss widened to $5.9 million from $1.3 million year over year, with loss per share reaching $0.54.
• This was driven by substantially increased research and development and general and administrative expenses.
• Despite a $15.0 million private placement bolstering cash resources expected to fund operations through the second quarter of 2027, management flagged substantial doubt about the company's ability to continue as a going concern.